Amgen Hopes For Broad T-VEC Label, But Is Prepared To Discuss Narrower Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
The big biotech reported a strong financial quarter while updating on several R&D and business catalysts, including the potential indications for its PCSK9 inhibitor.
You may also be interested in...
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.
“Now Is The Time” For Japan, Amgen Says; Inks Strategic Alliance With Astellas
After selling off its Japanese subsidiary in 2008, Amgen returns via an alliance and joint venture with Astellas, with the goal of establishing a wholly owned affiliate by 2020. But challenges remain in a country known for long memories.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.